Literature DB >> 10379721

Posttraumatic stress disorder symptoms related to psychosis and acute involuntary hospitalization in schizophrenic and delusional patients.

H Meyer1, T Taiminen, T Vuori, A Aijälä, H Helenius.   

Abstract

The aims of this study were: a) to assess the prevalence of posttraumatic stress disorder (PTSD) after an acute psychotic episode in schizophrenic and delusional patients, b) to explore which psychotic symptoms and aspects of treatment were associated with traumatization, and c) to compare the extent of the traumatic impact of psychosis and involuntary hospitalization. Forty-six schizophrenic and delusional patients were assessed with the Positive and Negative Syndrome Scale (PANSS), the Impact of Event Scale-Revised (IES-R), and the Clinician-Administered PTSD Scale (CAPS) at weeks 1 and 8 after acute psychiatric admission. Traumatic symptoms related to psychosis and coercive measures were scored separately. The prevalence of PTSD was found to be 11%. Sixty-nine percent of traumatic symptoms were related to psychosis and 24% to hospitalization. High PANSS score at week 8 was the strongest risk factor for the development of PTSD. Particularly positive and depressive/anxious symptomatology were associated with psychosis-related traumatic symptoms at both weeks 1 and 8. These data suggest that, in general, schizophrenic and delusional symptoms are more traumatic than the coercive measures used to control them.

Entities:  

Mesh:

Year:  1999        PMID: 10379721     DOI: 10.1097/00005053-199906000-00003

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  17 in total

1.  [Architectural modernization of psychiatric hospitals influences the use of coercive measures].

Authors:  T Rohe; T Dresler; M Stuhlinger; M Weber; T Strittmatter; A J Fallgatter
Journal:  Nervenarzt       Date:  2017-01       Impact factor: 1.214

2.  [Psychosis-induced posttraumatic stress disorder. A rarely diagnosed symptom].

Authors:  F Hohl-Radke
Journal:  Nervenarzt       Date:  2005-07       Impact factor: 1.214

3.  Effects of improved hospital architecture on coercive measures.

Authors:  Thomas Dresler; Tim Rohe; Markus Weber; Thomas Strittmatter; Andreas J Fallgatter
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

4.  Co-morbid PTSD and suicidality in individuals with schizophrenia and substance and alcohol abuse.

Authors:  Nicholas Tarrier; Alicia Picken
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-08-15       Impact factor: 4.328

Review 5.  How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association.

Authors:  Amélie M Achim; Michel Maziade; Eric Raymond; David Olivier; Chantal Mérette; Marc-André Roy
Journal:  Schizophr Bull       Date:  2009-12-03       Impact factor: 9.306

6.  Severe Mental Illness and Acute Stress: A Study of Service Utilization in a Conflict Zone.

Authors:  Demian Halperin; Tal Levy; Sofia Avissar; Gabriel Schreiber
Journal:  Psychiatr Q       Date:  2017-03

Review 7.  Psychiatric comorbidities and schizophrenia.

Authors:  Peter F Buckley; Brian J Miller; Douglas S Lehrer; David J Castle
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

Review 8.  Involuntary vs. voluntary hospital admission. A systematic literature review on outcome diversity.

Authors:  Thomas W Kallert; Matthias Glöckner; Matthias Schützwohl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06       Impact factor: 5.270

9.  Are there racial differences in the experience of harmful or traumatic events within psychiatric settings?

Authors:  Karen J Cusack; Anouk L Grubaugh; Eunsil Yim; Rebecca G Knapp; Cynthia S Robins; B Christopher Frueh
Journal:  Psychiatr Q       Date:  2007-06

Review 10.  Anxiety disorders and schizophrenia.

Authors:  Jacqueline E Muller; Liezl Koen; Seedat Soraya; Robin A Emsley; Daniel J Stein
Journal:  Curr Psychiatry Rep       Date:  2004-08       Impact factor: 8.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.